GINKGO BILOBA: PHARMACOLOGICAL AND TOXICOLOGICAL EFFECTS
Journal Title: Българско списание за обществено здраве (Bulgarian Journal of Public Health) - Year 2018, Vol 0, Issue 2
Abstract
This review study is based on data collected, summarized and analyzed by scientific journals and published electronic studies on updated information on the toxicological and positive pharmacological effects of Ginkgo biloba. Recently, leaf extract has been classified as a possible carcinogen for humans by the International Agency for Research on Cancer. Concerns about potential health hazards for the population are mainly due to the extensive and long-term use in humans and the available evidence of potential toxic effects in experimental animals. Prolonged clinical trials on the Ginkgo biloba leaf extract have led to the conclusion that there is significant evidence of carcinogenicity in mice based on an increased incidence of hepatocellular carcinoma and hepatoblastoma. Nevertheless, dry extract from Ginkgo plant is well known to its’ positive effects at memory loss and thrombosis in elderly patients.
Authors and Affiliations
Maya Yotova, Kaloyan Kaloyanov, Evgeni Grigorov
Keywords
Related Articles
- EP ID EP470767
- DOI -
- Views 40
- Downloads 0
Nutrition in children 1-5 years of age in Bulgaria - energy AND Macronutrient INTAKE
Children one to five years of age can be classified as risk population group concerning nutrition due to some particular physiological characteristics. Studies conducted up to now on children in this age group have estab...
THE ROLE OF THE NATIONAL REGISTRY IN PROVIDING LONG-TERM CARE FOR PATIENTS WITH RARE DISEASES
Rare diseases have become a policy priority in the common European public health. Limited number of patients and scarcity of knowledge and expertise – designate them as a distinctive domain of very high added-value for a...
STUDY AND ANALYSIS OF THE AWARENESS OF THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN BULGARIA
Health technology assessment is a well-established scientific methodology. It serves healthcare managers and policymakers to make informed decisions about new medicines and medical devices reimbursement. HTA is a relativ...
LEGAL ANALYSIS OF THE BULGARIAN LEGISLATION IN THE FIELD OF REGULATION OF PHARMACY PRACTICE FOR THE PERIOD 1903-2016
The purpose of this article is to track the legislative settlements in Bulgaria covering the regulation of the pharmaceutical market and the pharmacy services provided to the public. The main task for the authors is to i...
HEALTH TECHNOLOGY ASSESSMENT FOR TREATMENT OF CHRONIC HEPATITIS C REIMBURSED BY PUBLIC HEALTH FUND IN BULGARIA, 2016
In this study there have been defined the direct costs of treatment of chronic hepatitis C (CHC) by protease inhibitors (Pi), NS5B inhibitors (NS5Bi), NS5A inhibitors (NS5Ai) and calculated the coefficient of efficiency...